Point where the exception occurred to a point that can be specified byīe thrown from the point where it occurred and is Specifies that an exception will be thrown when semantic constraintsĪre violated and will cause a non-local transfer of control from the Of the Java SE platform: to provide portability and robustness. Neither of these approaches is compatible with the design goals Programming languages and their implementations react to such errorsīy peremptorily terminating the program other programming languagesĪllow an implementation to react in an arbitrary or unpredictable Is an attempt to index outside the bounds of an array. Semantic constraints of the Java programming language, the Java Virtual Machine signals this error Exception Analysis of Expressions 11.2.2. Compile-Time Checking of Exceptions 11.2.1. The Kinds and Causes of Exceptions 11.1.1. Diagnosis of distant metastasis (clinical M stage M0 versus M1a, M1b, M1c) and pelvic nodal disease (clinical N stage N1 versus N0) will be assessed by central radiological review.Table of Contents 11.1. Nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. Distant metastasis based on conventional imaging (clinical stage M1).Able to receive androgen deprivation therapy (ADT) for at least 13 months.Contraceptive use by men and female partners of men enrolled in the study who are of childbearing potential or are pregnant) should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies.Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.Candidate for radical prostatectomy with pelvic lymph node dissection as per the investigator.High-risk disease defined by a total Gleason Sum Score greater than equal to (>=) 4+3 (=Grade Groups 3 5) and >=1 of the following 4 criteria: a) Any combination of Gleason Score 4+3 (= 3) and Gleason Score 8 (4+4 or 5+3) in >= 6 systematic cores (with >=1 core Gleason Score 8 included) b) Any combination of Gleason Score 4+3 (=GG 3) and Gleason Score 8 (4+4 or 5+3) in >=3 systematic cores and Prostate-specific antigen (PSA) >=20 ng/mL (with >= 1 core Gleason Score 8 included) c) Gleason Score >=9 (=GG 5) in at least 1 systematic or targeted core d) At least 2 systematic or targeted cores with continuous Gleason Score >=8 (=GG 4), each with > 80 percent (%) involvement.Histologically confirmed adenocarcinoma of the prostate.
Linguagem do proteus 8.4 plus#
An open-label sub-study comparing apalutamide plus ADT before and after RP with pLND with standard of care treatment will be initiated at selected sites upon notification by the sponsor. The safety will be monitored throughout the study. Participants will undergo efficacy, pharmacokinetics and biomarker evaluations. The end of study (study completion) is defined as last participant assessment at study site with approximate study duration of 8 years. Cycle 1 Day 1 will start within 3 days after randomization) and follow-up phase. The study includes screening phase (approximately up to 35 days before randomization), treatment phase (the planned Treatment Phase will include a total of 12 treatment cycles of apalutamide or placebo 6 cycles prior to RP with pLND (Cycle 1 through Cycle 6) and 6 cycles after RP with pLND (Cycle 7 through Cycle 12). ERLEADA (apalutamide, also known as JNJ-56021927 and ARN-509) is an orally available, non-steroidal small molecule, which acts as a potent and selective antagonist of the androgen receptor (AR), currently being developed for the treatment of prostate cancer. This study is designed to evaluate if androgen blockade administered prior to and after RP with pLND will increase the rate of pathological complete response (pCR) and lead to better overall outcomes. It is hypothesized that androgen blockade prior to and after RP with pLND may improve outcomes for participants at the highest risk for recurrence. A systemic therapy that eradicates micrometastatic disease is needed to improve survival in high-risk participants undergoing RP with pLND. High-risk prostate cancer accounts for approximately 15 percent (%) of newly diagnosed prostate cancers. Why Should I Register and Submit Results?.